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Polymorphic expression of CYP2D6 contributes to the wide range of activity observed for this 
clinically important drug metabolizing enzyme. In this report we describe novel CYP2D7/2D6 
hybrid genes encoding non-functional and functional CYP2D6 protein and a CYP2D7 variant that 
mimics a CYP2D7/2D6 hybrid gene. Five-kilobyte-long PCR products encompassing the novel 
genes were entirely sequenced. A quantitative assay probing in different gene regions was 
employed to determine CYP2D6 and 2D7 copy number variations and the relative position of 
the hybrid genes within the locus was assessed by long-range PCR. In addition to the previously 
known CYP2D6*13 and *66 hybrids, we describe three novel non-functional CYP2D7-2D6 
hybrids with gene switching in exon 2 (CYP2D6*79), intron 2 (CYP2D6*80), and intron 5 
(CYP2D6*67). A CYP2D7-specific  T-ins in exon 1 causes a detrimental frame shift. One subject 
revealed a CYP2D7 conversion in the 5′-flanking region of a CYP2D6*35 allele, was otherwise 
unaffected (designated CYP2D6*35B). Finally, three DNAs revealed a CYP2D7 gene with a 
CYP2D6-like region downstream of exon 9 (designated CYP2D7[REP6]). Quantitative copy 
number determination, sequence analyses, and long-range PCR mapping were in agreement 
and excluded the presence of additional gene units. Undetected hybrid genes may cause over-
estimation of CYP2D6 activity (CYP2D6*1/ *1 vs * 1/hybrid, etc), but may also cause results 
that may interfere with the genotype determination. Detection of hybrid events, “single” and 
tandem, will contribute to more accurate phenotype prediction from genotype data.
Keywords: CYP2D6, hybrid genes, CYP2D6*35B, CYP2D6*67, CYP2D6*79, CYP2D6*80, CYP2D6 poor metabolizer
carries a CYP2D7 conversion in exon 9). CYP2D7/2D6 hybrid genes 
are recombination products that likely resulted from large deletion 
events that fused respective ends of both genes together and carry 
a T-insertion in exon 1 that causes premature termination. These 
hybrids are non-functional. We have recently described three alle-
les carrying non-functional hybrids upstream of intact CYP2D6*1 
and *2 genes (CYP2D6*76 + *1, *77 + *2, and *78 + *2). Notably, 
these alleles presented as gene duplications when tested on certain 
platforms/assays and hence may be misclassified as CYP2D6*1xN 
and *2xN, if not fully characterized (Gaedigk et al., 2010). Kramer 
et al. (2009) also have observed CYP2D7/2D6 hybrid genes in single 
and tandem arrangements providing further evidence that hybrid 
genes may not be as rare as generally believed. A graphical overview 
is provided in Figure 1.
Testing of hybrid genes is rarely performed because their detec-
tion typically requires long-range PCR which is not amenable to 
automation (Figure 1). Hence, despite major CYP2D6 genotyping 
efforts and the development of many commercially available plat-
forms and test kits, hybrid genes remain elusive. In order to detect 
CYP2D7/2D6 hybrid genes on a routine basis, we have modified our 
long-range (XL) PCR to not only generate the 6.6-kb long CYP2D6-
specific amplicon which is subsequently used for genotyping, but 
IntroductIon
CYP2D6 is a highly polymorphic drug metabolizing enzyme. To 
date 80 allelic variants including those described in this report 
and numerous subvariants have been defined by the cytochrome 
P450 nomenclature committee1. The collection of known alleles 
comprise variants encoding no, reduced, full, or ultrarapid CYP2D6 
activity and give rise to corresponding poor (PM), intermediate 
(IM), extensive (EM), and ultrarapid (UM) metabolizer pheno-
types. While  the  most  frequent  sequence  variations  are  single 
nucleotide polymorphisms (SNPs) or small insertions/deletions, 
this gene locus also undergoes major recombination events creat-
ing alleles harboring large deletions, duplications, multiplications, 
conversions, and combinations thereof (Zanger et al., 2004; Gaedigk 
et al., 2007; Kramer et al., 2009; Gaedigk et al., 2010). The CYP2D 
gene locus contains direct repeat regions and highly homologous 
gene units which facilitate unequal crossing-over that can lead to 
allelic variants with large deletions and duplications (Hastings et al., 
2009). Most prominent examples are the CYP2D6*5 gene deletion, 
CYP2D6*1xN, *2xN, and *4xN gene duplications/multiplications 
and gene tandems such as CYP2D6*36 + *10 (the CYP2D6*36 gene 
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Materials and Methods
subjects
The  subjects  included  in  this  analysis  gave  written  informed 
consent to participate in studies involving genetic testing of the 
CYP2D6 gene. Studies were approved by the Ethic Committees or 
Institutional Review Boards of the Institutions where the partici-
pants were enrolled (cohort 1: Children’s Mercy Hospital, Kansas 
City, n = 490; cohort 2: University of Montreal, CHU Ste-Justine, 
n = 268; cohort 3: the University of the West Indies, n = 279; 
Morehouse School of Medicine, Atlanta, n = 272; or independ-
ent institutional review boards for samples obtained at Bassett 
Healthcare, Cooperstown, NY, n = 1 and Ordway Research Institute 
Drug Development Center, Albany, NY, n = 1). One sample was 
also generate duplication-specific and hybrid-specific amplicons 
(Gaedigk et al., 2010) in a   convenient triplex reaction. Prospective 
and retrospective application of this strategy resulted in the dis-
covery of 12 subjects, which were hybrid-positive, in addition to 
the CYP2D6*13 (EU098008) and CYP2D6*66 (EU093102) index 
cases previously characterized. We also found an additional subject 
positive for the CYP2D6*76 + *2 tandem hybrid corroborating our 
previous finding (Gaedigk et al., 2010).
The goal of the present study was to characterize the hybrid 
genes within the CYP2D locus in these subjects in detail, assess their 
functionality using in vivo phenotype data with dextromethorphan 
as probe drug in a subset of individuals and describe strategies for 
their detection and analysis.
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Figure 1 | Overview of the CYP2D7/2D6 hybrid genes. CYP2D6, CYP2D7 , 
and CYP2D8 genes are shown in light gray, red, and dark gray boxes, 
respectively. The 600-bp repeat element immediately downstream of exon 9 is 
shown in blue. CYP2D6 and CYP2D7-derived repetitive elements (REP) are in 
red and light gray; REP-DEL indicates a fused repeat element generated by a 
large deletion involving parts of those elements from both genes. PCR 
fragments generated are represented as lines and their sizes are given in 
kilobyte. Red and black endpoints denote primer specificity to CYP2D6 and 
CYP2D7. (A) Graph represents the CYP2D reference locus. Areas affected by 
large deletions and implicated in CYP2D7/2D6 hybrid formation and the 
CYP2D6*5 gene deletion are as indicated. (B) Graphic display of the CYP2D6*5 
gene deletion allele. XL -PCR amplicons utilized for detection are shown. 
(C) Graphic display of CYP2D7/2D6 hybrid genes and their detection by 
amplification of fragment H. Other depicted fragments are only amplified, if 
respective rearrangements are present in a sample. (D) Representation of an 
allele with a CYP2D7 gene lacking the 1.6-kb spacer. This CYP2D7 variant also 
supports formation of fragment H although the CYP2D7/2D6 switch occurs in 
the downstream region.www.frontiersin.org  October 2010  | Volume 1  | Article 121  |  3
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CYP2D6*1/*1 [Coriell ID NA17111]) with the following CYP2D7-
specific  primers:  5′-  TCCGACCAGGCCTTTCTACCAC  and 
5′-CACCAGAAAGCTGACGACACGAGA. Exon 1 and the 276 bp 
of the upstream region were sequenced as described above.
characterIzatIon of the CYP2D locus contaInIng hybrId-
duplIcatIon tandeMs
Long-range PCRs covering different regions of the CYP2D locus 
were  performed  with  primers  specific  for  CYP2D6,  CYP2D7, 
and CYP2D8. XL-PCR was carried out as described previously 
(Daly et al., 1996, Gaedigk et al., 2010). Figure 1 provides a graphical 
display of the approximate region covered in the various reactions. 
Note that the 8-kb amplicon depicted in Figure 1 corresponds to 
the XL-PCR first devised by Daly et al. (1996) for the detection of 
CYP2D6*13 and *16.
genotypIng assay detectIng the CYP2D7 exon 9 conversIon 
and CYP2D7[REP6]
A  597-bp-long  amplicon  was  amplified  with  a 
CYP2D7-specific  forward  primer  directed  at  exon  9 
(5′-AGCCACTCTCGTGTCGTCAGCTT) and a CYP2D6-specific 
reverse primer binding downstream of the gene (same binding 
site as the primer used to generate the 6.6-kb-long genotyping 
template; 5′-CGACTGAGCCCTGGGAGGTAGGTAG). A second 
pair of CYP3A7 primers was added to the reaction that generated 
an 860-bp-long product (internal control) independently of the 
CYP2D6 genotype. PCR was carried out in 8-μl reactions with 
RedJumpStart  DNA  polymerase  (Sigma)  and  ∼15-ng  genomic 
DNA. Cycling conditions comprised an initial denaturing step for 
3 min at 94ºC that was followed by 42 cycles at 94ºC for 10 s, 68ºC 
for 10 s, and 72ºC for 30 s and a final hold at 10ºC. PCR fragments 
were subsequently resolved by agarose gel electrophoresis.
An RFLP-based assay discriminating CYP2D6 from CYP2D7 
exon  9  sequences  was  carried  out  as  following.  A  PCR  prod-
uct was amplified with primers encompassing exon 9 (forward 
primer  5′-GGCAAGGGTAACTGACATCTG;  reverse  primer 
5′-CCTGGGAGGTAGGTAGCCCTG).  PCR  was  carried  out  as 
described above, but an annealing temperature of 58ºC. The PCR 
products were subsequently incubated overnight at 37ºC with the 
restriction enzyme NcoI and then separated by agarose gel electro-
phoresis. CYP2D6-derived sequences were cut once (591 and 184 bp) 
while CYP2D7-derived sequences remained uncut (775 bp).
results
Twelve subjects were identified by the triplex XL-PCR to carry 
CYP2D7/2D6 hybrid gene structures (Table 1).
The hybrid genes presented themselves by the presence of a 5-kb 
amplicon (fragment H) as shown in Figure 2A. The hybrid was 
confirmed by “solo” XL-PCR (Figure 2B) and its location imme-
diately downstream of CYP2D8 demonstrated by the generation of 
XL-PCR amplicons that span CYP2D8 and different regions within 
the hybrid (the product covering CYP2D8 through CYP2D6 intron 
6 is shown in Figure 2C). Also, as depicted in Figure 2C, none 
of the subjects was positive for a duplication event, i.e. produced 
the duplication-specific 3.5-kb-long XL-PCR product. Presence of 
other rearranged genes was excluded by a quantitative copy number 
assay (Ramamoorthy et al., 2010).
obtained through physician-requested diagnostic testing (Quest 
Diagnostics Nichols Institute). Genomic DNA was isolated from 
whole blood or saliva specimen collected in Oragene DNA sam-
ple collection disks (DNA Genotek, Kanata, ON, Canada) using 
column-based procedures and stored at 4ºC.
cyp2d6 actIvIty deterMIned by in vivo phenotypIng
Urinary  concentrations  of  dextromethorphan  (DM)  and  its 
metabolite dextrorphan (DX) were determined by reversed-phase, 
high-performance liquid chromatography as described (Blake et al., 
2007). Phenotype classification was made based on the urinary DM/
DX ratio in 4-, 5-, and 12-h urine collections sampled in Kansas City 
and Atlanta, Trinidad and Cooperstown, respectively. UM, EM, IM, 
and PM categories are as defined by Gaedigk et al. (2008).
detectIon of hybrId genes by long-range pcr
The simultaneous detection of the CYP2D6 gene, hybrids and duplica-
tions were achieved by long-range (XL) PCR essentially as described 
in detail elsewhere (Gaedigk et al., 2010). Briefly, this XL-PCR triplex 
reaction produced a 6.6-kb-long amplicon from the CYP2D6 gene, 
a 5-kb-long fragment (fragment H) (Figure 1) and a 3.5-kb-long 
fragment from gene duplications containing a CYP2D6[REP6] down-
stream sequence. Hybrid genes support formation of fragment H 
given that they are comprised of a CYP2D7 sequence upstream of exon 
1 and a CYP2D6-specific sequence downstream of CYP2D6 exon 9. 
XL-PCR was performed at a final concentration of 5% DMSO with 
KAPA Long Range HotStart DNA Polymerase (KAPA Biosystems, 
Woburn, MA, USA) as prescribed by the manufacturer’s protocol. 
Annealing temperature was 68ºC and extension times 1 min/1 kb. 
Reaction volumes were 8 μl containing 15–25 ng genomic DNA. 
Typically 1.5–3 μl of PCR product were analyzed by agarose gel 
electrophoresis. Primers and PCR amplicon lengths are given in 
(Gaedigk et al., 2010). Genotype analysis was performed on diluted 
triplex XL-PCR amplicons using PCR-RFLP-based assays as previ-
ously described (Gaedigk et al., 2010) to determine whether the hybrid 
genes carried CYP2D6 or 2D7-specific sequence variations in exons 
1 and 9, respectively. For subsequent sequence analysis, fragment H 
was generated as sole amplicon under identical conditions. Genotype 
analysis for all other CYP2D6 variants was either carried out by PCR-
RFLP analysis as described in detail (Gaedigk et al., 2008) or using 
predesigned TaqMan assays (Applied Biosystems, Foster City, CA, 
USA). The latter were performed in 8-μl reaction volumes containing 
XL-PCR template diluted at least 1000-fold, 1× ProbeFast qPCR kit-
ABI Prism ready mix (KAPA Biosystems, Woburn, MA, USA) and 1× 
TaqMan probes. Cycling parameters were as prescribed for the PCR 
kit and cycle number performed ranged from 35 to 45.
dna sequence analysIs
For sequence analysis, fragment H was purified with the GenElute 
PCR Clean-Up Kit (Sigma, St Louis, MO, USA) and entirely sequenced 
using BigDye terminator v3.1 cycle sequencing chemistry and a 3730 
capillary DNA analyzer (Applied Biosystems). Sequences deposited in 
GenBank (M33387, M33388, AY545216, EU098008, and EU093102 
served as reference sequences for CYP2D7, CYP2D6, CYP2D6*13 and 
*16, respectively. To determine the CYP2D7 upstream sequence in 
more detail, a 5-kb-long amplicon was generated from five subjects 
(CYP2D6*1/*5; CYP2D6*4/*4; CYP2D6*5/*5; CYP2D6*2/*41, and Frontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    October 2010  | Volume 1  | Article 121  |  4
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Table 1 | Summary of cases.
Subject #  Origina  ethnicityb  genotype  Activity score  Predicted Phenotypec  DM/DXd
Index Case  Kansas City  C  *5/ *66  0  PM  1.511 (PM)
Case 1  Quebec  C  *9/*66  0.5  IM  n/a
Case 2  Quebec  C  *5/*66  0  PM  n/a
Case 3    C  *1/*66  1  slow-EM  n/a
Case 4  Cooperstown  C  *5/*66d  0  PM  2.17502 (PM)
Case 5  Quebec  C  *6/ *66[variant]f  0  PM  n/a
Case 6  Albany  C  *6/*67  0  PM  n/a
Case 7  Corielle  AA  *29/ *80  0.5  IM  n/a
Case 8  Quebec  C  *2/*79  1  slow-EM  n/a
Case 9  Cooperstown  C  *4/*35B  1  slow-EM  0.03783 (IM)
Case 10  Kansas City  AA  2D7[REP6] + *1/*17g  1.5  fast-EM  n/a
Case 11  Trinidad  Afro-Trinidadian  2D7[REP6]*1/ *2g  2  fast-EM  0.02102 (slow-EM)
Case 12  Atlanta  AA  2D7[REP6]*1/ *2g  2    0.003 (fast-EM)
Case 13  Trinidad  Indo-Trinidadian  *4/ *76 + *1  1    0.0094 (fast-EM)
aOrigin denotes the city, province or state the participant was living in when enrolled; Coriell denotes that the DNA sample was obtained from the Coriell Institute. 
bC, Caucasian; AA, African American. cPredicted phenotypes are according to Gaedigk et al (Gaedigk et al., 2008). dObserved phenotype using urinary ratio (DM/DX) 
as measure of CYP2D6 activity; corresponding phenotype group is shown in brackets. n/a, phenotype not available. eCoriell ID NA17165. fThis CYP2D6*66A was 
partially sequenced (exon 7 switch region). gThe CYP2D6*1 allele carries a CYP2D7[REP6] (Figure 3, top panel).
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Figure 2 | Long-range (XL) PCr products generated from hybrid genes and 
control samples. Fragment designation corresponds to that provided in Figure 1 
and used throughout this manuscript. The genotypes of the cases are shown in 
Table 1. PCR product lengths are given in kilobyte to the right, marker sizes on the 
left. All PCRs were carried out on genomic DNA. (A) Triplex XL -PCR showing the 
formation of fragment A (entire CYP2D6 gene), fragment B (presence of gene 
duplication), and fragment H (indicating the presence of a CYP2D7/2D6 hybrid 
gene). (B) Fragment H was generated by itself. Note that this fragment is weak in 
the triplex reaction in panel A for case 9, but unequivocally present when amplified 
“solo” . (C) As expected from sequence data, cases 5, 6, and 7 generated a PCR 
product spanning CYP2D8 to CYP2D6 intron 6. CYP2D6*66 (index case) and case 
9 serve as negative controls (see Figure 3 for hybrid details).www.frontiersin.org  October 2010  | Volume 1  | Article 121  |  5
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In contrast, subject (case 9) was negative for the T-insertion and 
encoded an open reading frame that corresponded to CYP2D6*35 
and  therefore  the  formation  of  active  protein.  However,  the 
upstream region contained a 110-bp-long cassette (or inversion) 
that corresponded to CYP2D7 and contained the primer binding 
site for the primer used to generate fragment H (Table 1). When this 
subject was initially genotyped using a shorter XL-PCR template 
(Gaedigk et al., 1999), we determined a CYP2D6*4/*4 genotype, 
which was discordant with the subject’s phenotype. In contrast, 
analysis with our current procedure using a 6.6-kb-long template, 
two alleles were detected and the revised CYP2D6*4/*35 genotype 
was consistent with the DM/DX ratio of 0.03783. While we could 
not explain this discrepancy at the time this subject was first geno-
typed over ten years ago, these findings are consistent with the dis-
covery of the CYP2D7 conversion cassette that prevents binding of 
the CYP2D6-specific primer we originally utilized (primer binding 
site is shown in Figure 4). To confirm the CYP2D6 conversion, and 
determine additional sequence in the upstream region, the 6.6-kb-
long XL-PCR product was sequenced in addition to fragment H. 
This allele was designated CYP2D6*35B and has been catalogued 
under accession number HM641838.
Sequence analysis of the hybrid genes amplified from cases 10, 11, 
and 12 revealed a CYP2D7 gene lacking the 1.6 kb spacer sequence 
that is typically found downstream of CYP2D7 between a 600 bp 
repeat region and REP7 (Figures 1 and 3 and Gaedigk et al., 2010). 
Taken together, these results suggested that large deletion events 
removed parts of the 3′-region of CYP2D7, the intergenic region 
and parts of the 5′-region of CYP2D6 to form CYP2D7/2D6 hybrid 
genes as displayed in Figure 1.
Sequence analysis revealed that three of the 12 CYP2D7/2D6 
hybrid-positive cases (Table 1) were identical and corresponded 
to the CYP2D6*66 sequence previously described for our index 
case and deposited under accession number EU093102. This rese-
quencing effort identified a G-insertion (TCAGGGAGGGAT) 
in exon 4 that introduced an additional frame shift and fur-
ther corroborated the non-functional nature of the hybrid (the 
original sequence EU093102 was corrected accordingly). One 
subject  (case  5)  had  a  hybrid  with  an  identical  sequence  in 
the CYP2D7/2D6 switch region in exon 7 (Figure 3), but dif-
fered from CYP2D6*66 in six positions, three of them being 
upstream of exon 1 (Figure 4). This allele is referred to here as 
CYP2D6*66[variant].
Three subjects (cases 6, 7, and 8) had hybrid genes with a switch 
from CYP2D7 to CYP2D6 in exon 2, exon 3, and exon 5, respectively 
(Figure 3). These alleles were designated by the nomenclature com-
mittee as CYP2D6*79, *80, and *67; their corresponding GenBank 
accession numbers are HM641839, HM641840, and EU098009. 
Notably, all three variants carry a T-insertion in exon 1, a hallmark 
feature of CYP2D7, which does not support formation of functional 
protein due to premature translation termination.
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Figure 3 | graphic overview of hybrid alleles and their CYP2D7/2D6 switch 
region. CYP2D7 and CYP2D6 portions are shown in red and gray boxes, 
respectively. The CYP2D7 conversion in CYP2D6*35[variant] is shown as a red box 
upstream of exon 1. Switch regions are indicated in green. The red arrow notes a 
T-insertion in CYP2D7 exon 1 relative to CYP2D6. The hybrid sequences were 
aligned with CYP2D7 (M33387) and CYP2D6 (M33388) reference sequences to 
approximate the switch region. For completion, the graph also shows previously 
reported CYP2D6*76 + *1, *77 + *2, and *78 + *2 tandem hybrids (Gaedigk et al., 
2010) as well as the CYP2D6*13 and *16 alleles (no reference sequences deposited 
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(n = 8), or did not fit into those categories (unknown, other and 
admixed, n = 10). Among those we discovered our CYP2D6*66 
index case (frequency of CYP2D6*66 in the Caucasian subset was 
0.1%) and one CYP2D7[REP6] carrier (f = 0.6% in the African 
American subset). Cohort 2 was a predominantly Caucasian cohort 
collected in Canada and the US and consisted of 268 subjects 
(n = 232 Caucasian, n = 13 African American, n = 9 Hispanic, n = 4 
Asian, n = 10 admixed or of other ethnicity). Two CYP2D6*66, one 
*66[variant], one novel *79 hybrid and one *77 + *2 tandem hybrid 
allele were found in the Caucasians of this cohort (frequency of 
all single hybrids combined was 4/232 or 0.86%). A third cohort 
was composed of 174 Indo Trinidadians and 105 Afro Trinidadians 
among which only a single CYP2D7[REP6] was discovered in a sub-
ject with African ancestry (f = 0.5%). Notably an Indo Trinidadian 
subject revealed a CYP2D6*76 + *1 tandem hybrid, an allele so 
far observed in only one other subject who was African American 
(Gaedigk et al., 2010). To estimate the frequency for CYP2D6*35B, 
we screened an additional 28 carriers of CYP2D6*35 from cohort 
1. However, none were detected. Given a frequency of about 5% of 
CYP2D6*35 in Caucasians (de Leon et al., 2009) the CYP2D6*35B 
subvariant appears to be rare (<0.1%).
An alignment of the hybrid genes with CYP2D6 and CYP2D7 
reference sequences revealed that the hybrid genes matched with the 
CYP2D7 sequence given in ENSG00000205702 (Ensemble database), 
but not GenBank entry M33387 in the immediate upstream region 
of exon 1. Due to the differences between the two genes in this region, 
it is a preferred binding site for CYP2D6-specific gene   amplification 
Due to the absence of the spacer sequence, the CYP2D6-specific 
reverse primer bound to this gene unit and supported amplification 
of a CYP2D7/2D6 hybrid PCR product. In line with primer design 
(CYP2D7-specific forward and CYP2D6-specific reverse primer), 
the CYP2D7[REP6] gene was also detected by an assay we origi-
nally developed to screen genomic DNA for the presence of the 
exon 9 conversion in CYP2D6 variants such as CYP2D6*4N and 
*36. As shown in Figure 5A, cases 10–12 produced a PCR product 
suggesting that the CYP2D7/2D6 switch occurred downstream of 
exon 9. In contrast, these subjects were negative for the exon 9 con-
version when the 6.6-kb-long CYP2D6-specific XL-PCR product 
was used as genotyping template excluding the possibility that the 
amplicon shown in Figure 5A is derived from an allele similar to 
CYP2D6*4N or *36 (Figure 5B). The quantitative copy number 
assay (to be published elsewhere), revealed two copies for CYP2D6 
and CYP2D7, respectively indicating that no additional gene units 
are present. Taking all findings together we concluded that this 
“hybrid” is most likely derived from the CYP2D7 gene possessing 
a CYP2D6-like downstream region, i.e., REP6 lacking the 1.6-kb-
long spacer. Furthermore, because all three cases have a CYP2D6*1 
allele in common, CYP2D7[REP6] is most likely associated with 
CYP2D6*1 as depicted in Figure 3.
Following are details for three cohorts for which a full set of 
experimental and demographic data were available to estimate 
hybrid allele frequencies: cohort 1 consisted of 490 subjects col-
lected in the US who defined themselves as Caucasian (n = 329), 
African American (n = 83), Asian (n = 50), Hispanic (n = 10), Indian 
M33388
case 9
EU098008
case 8
case 7
case 6
index case        
cases 1-3
case 5
cases 10-12
GC162806  
GC162807 
GC162808
ENSG000002
05702
n=7 alleles
n=3 alleles
M33387
M33388
Position
2D6 *35B *13 *79 *80 *67 *66 *66 [var] 2D7 
[REP6]
*76   *77   
*78 2D72 D7 2D72 D7
>1189 >-431 2D6 2D6 2D7 2D7 2D72 D7 2D72 D7 2D72 D7 2D72 D7 2D72 D7
1,189 -431 CTXXXXXXXXTXXT
1,266 -354 AGXXXXXXXXGXXG
1,286 -334 G CXX XXXXXXCXXC
1,289 -331 T GXX XXXXXXGXXG
1,292 -328 C TXX XXXXXXTXXT
1,293 -327 A GXX XXXXXXGXXG
1,299 -321 C GXX XXXXXXGXXG
1,300 -320 A GXX XXXXXXGXXG
1,344 -276 CTTTTTTTTTTTT T
1,345 -275 CTTTTTTTTTTTT T
1,348 -272 CTTTTTTTTTTTT T
1,352 -268 GAAAAAAAAAAAA A
1,353 -267 GCCCCCCCCCCCC C
1,388 -232 GCCCCCCCCCCCCC
1,395 -225 AGGGGGGGGGGGGG
1,403 -217 GGGGGGGGGGGGGC
1,417 -203 CTTCCTC TTTTTCC
1,418 -202 GGGAAGAGGGGGAG
1,431 -189 TTTTTTTTTTTTTC
1,434 -186 ::::::::::::: C
1,434 -186 ::::::::::::: A
1,434 -186 ::::::::::::: C
1,465 -155 CCCCCCCCCCCCCG
1,466 -154 AAAAAAAAAAAAAG
1,482 -138 AGGAGGGGGGGGGG
1,534 -86 TTCTTCTCTTTTTT
1,602 -18 TTGG GGGGGGGGGG
1,618 -2 GGCC CCCCCCCCCC
1,619 -1 TTCC CCCCCCCCCC
M33388
Figure 4 | Comparison of hybrid sequences upstream of exon 1 to CYP2D6 
and CYP2D7 references. CYP2D6 sequences are highlighted in yellow, CYP2D7 
in green and sequence variation deviating from both in orange. Position numbers 
are given according to M33388 (first column, 1 = first nucleotide in M33388; 
second column, −1 = first nucleotide upstream of ATG start codon. The forward 
primer binding site for fragment H is shown in darker green in the M33387 
reference sequence and limits the sequence information obtained from the 
hybrids (X denotes no sequence). A commonly used CYP2D6-specific primer 
binding site is shown in darker yellow in the M33388 reference sequence. For 
CYP2D6*35B ∼1.5 kb of upstream region was sequenced.www.frontiersin.org  October 2010  | Volume 1  | Article 121  |  7
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genes via translocation, insertion or deletion have recently been 
reviewed by Hastings et al. (2009). The CYP2D locus contains three 
highly homologous genes (CYP2D6, 2D7, and 2D8) along repeat 
motifs constituting a perfect target for homologous recombination 
events. Such events are believed to be the mechanism by which 
CYP2D7/2D6 hybrids were formed: the deletion of a 3′-portion 
of the CYP2D7, the intergenic region and a 5′-portion of CYP2D6 
results in a fused gene unit composed of CYP2D7 and CYP2D6. 
The first hybrid genes described were CYP2D6*13 and *16 in which 
the switch occurred in intron 1 and somewhere between intron 7 
and exon 8, respectively (Panserat et al., 1995; Daly et al., 1996) 
(Figure 3); these have recently also been detected by Kramer et al. 
(2009). We now report additional hybrids switching to CYP2D6 
in exon 2, intron 2, and intron 5, a variant of CYP2D6*66 and 
a CYP2D7 variant with a CYP2D6-like REP6 region mimicking 
a CYP2D7/2D6 hybrid. The majority of subjects carrying hybrid 
genes or a hybrid in tandem arrangements (Gaedigk et al., 2010) 
are of Caucasian origin (Table 1). To date we have identified only 
one subject of African ancestry with a “single” hybrid gene (case 
and frequently targeted by investigators. We resequenced CYP2D7 
of 10 alleles of selected subjects with CYP2D6*1/*1, *1/*5, *4/*4, 
*5/*5, and *2/*41 genotypes to explore sequence variations within 
the upstream region of CYP2D7. As summarized in Figure 4, seven 
alleles corresponded to ENSG00000205702 and three exhibited CA 
at positions −203/−202, which was also observed in some of the 
hybrids. However, none matched M33387.
dIscussIon
The CYP2D6 gene locus has been extensively studied for allelic 
variation and ethnic differences. It is fair to state that this gene is 
amongst the most polymorphic drug metabolizing genes with 80 
defined allelic variants, numerous recognized subvariants1, many 
variants with trivial names and some that remain unnamed. In 
addition to simple sequence variations such as SNPs, the locus is 
also known for major recombination events that created gene dupli-
cations, multiplications, conversions, and deletions (Steen et al., 
1995; Kramer et al., 2009). Mechanisms that lead to changes in gene 
copy number and new combinations of exons between different 
M pos control
neg control
H2O
case 7
case 10
case 11
case 12
*2/*36
*29/*80
2D7[REP6]+*1/*17
2D7[REP6]*1/*2
2D7[REP6]*1/*2
*2/*41
0.5
kb bp
860 (IC)
597
775
591
184
1
0.5
1
A
B
Figure 5 | genotype analysis for CYP2D7 exon 9 conversion and 
CYP2D7[REP6]. M, 100-bp ladder. Cases, positive, and negative control DNAs 
and their respective genotypes are as indicated. Selected marker bands are given 
in kilobyte to the left; PCR product and restriction fragment lengths are shown to 
the right in base pair. The top panel (A) shows a duplex assay performed on 
genomic DNA that detects the CYP2D6 exon 9 conversion present in e.g., 
CYP2D6*36 and alleles carrying a CYP2D7[REP6]. The forward primer is specific 
for CYP2D7 exon 9 and the reverse primer for CYP2D6 binding to the REP6 
junction (see Figure 1). A second primer pair served as internal control (IC). 
Samples positive for CYP2D6*36 or CYP2D7[REP6] produced a 597-bp long 
amplicon in addition to the 860-bp-long IC product. The bottom panel (B) shows a 
RFLP-based assay performed on the 6.6-kb long CYP2D6-specific genotyping 
template. Uncut PCR product (775 bp) is indicative of a CYP2D7 exon 9-derived 
sequence on a CYP2D6 background. The CYP2D6*2/*36 control DNA sample is 
positive for CYP2D7 exon 9 in both assays, while cases 10, 11 and 12 showed a 
CYP2D6-derived pattern in the RFLP assay (591 + 184 bp).Frontiers in Pharmacology  |  Pharmacogenetics and Pharmacogenomics    October 2010  | Volume 1  | Article 121  |  8
Gaedigk et al.  CYP2D6* hybrid genes
intron 6, and exon 9) and two regions each of CYP2D7 and CYP2D8 
(to be publishes elsewhere) and have applied these assays to the 
cases reported here. Results were consistent with all genotyping 
results obtained from genomic DNA and XL-PCR templates as well 
as additional XL-PCR amplifications spanning different regions of 
the CYP2D gene locus (Figures 1C,D and 2).
Of the four additional CYP2D6*66 alleles we have resequenced, 
one differed in six positions suggesting that not all CYP2D6*66 
may have arisen from the same recombination event or that one 
variant accumulated additional SNPs. The CYP2D6*66[variant] 
matched with the apparently more common CYP2D7 sequence 
corresponding to ENSG00000205702, while CYP2D6*66 aligned 
with the minor CYP2D7 allele (Figure 4).
Interestingly, one initially discordant subject (case 9) revealed 
a CYP2D7 conversion in the upstream region of a CYP2D6*35 
(designated CYP2D6*35B) that first prevented its detection due 
to the lack of the CYP2D6 primer binding site. Furthermore, this 
allele supported the formation of a PCR product described by Daly 
et al. (1996) to detect CYP2D6*16; hence the initial CYP2D6*4/*16 
genotype assignment. When the genotyping template, however, was 
generated with a CYP2D6 primer located further upstream, the 
CYP2D6*35B allele was detected. This case nicely illustrates how 
unknown sequence variability in a region that is frequently used 
as primer binding site can cause an incorrect genotype assignment 
that is discordant with phenotype.
Hybrid  genes  remain  largely  undetected  using  conventional 
genotyping strategies or platforms. However, depending on primer 
binding sites utilized and which part of a hybrid gene is derived 
from CYP2D6 and CYP2D7, amplification may or may not pro-
ceed and thereby interfere with the genotype call. For example, if 
the CYP2D6 portion is amplified, a wild-type call for a particular 
SNP would “mimic” the presence of a wild-type or CYP2D6*1 allele. 
If no amplification takes place, the result reflects only that of the 
other allele leading to a homozygous genotype call. Thereby, “hid-
den” (undetected) hybrids may cause over-estimation of a subject’s 
phenotype (e.g. CYP2D6*1/*1 vs *1/hybrid) or may interfere with a 
genotyping results by producing unexplained/inconsistent genotyp-
ing results preventing unequivocal assignments. Indeed, a subset of 
the subjects described by Kramer et al. (2009) were triaged for further 
characterization because of inconsistencies including data that could 
not be interpreted or homozygosity for rare alleles suggesting allele 
drop out or the presence of a hybrid gene. This strategy was also 
pursued by us to identify our first hybrid genes including our index 
case that was first published as CYP2D6*5/*16 and later revised to 
CYP2D6*5/*66 (Gaedigk et al., 1999; Gaedigk and Coetsee, 2008).
Phenotype information, i.e. urinary metabolic ratios of DM/DX 
was available for four subjects in addition to case 9 described in 
detail in the section “Results” and the index case. For eight subjects 
phenotyping with DM was either not part of the study protocol 
or there was not sufficient urine available for analysis (case 10). 
Consistent with genotype, the index case and case 4 were pheno-
typic PMs with a DM/DX ratio > 0.3. Without information for 
hybrid alleles, these two cases along case 2, 5, and 6 would have 
been assigned homozygous null/null genotypes (Table 1), which 
would be consistent with the observed phenotype. The DM/DX 
ratios observed for cases 11–13 were also in general agreement. In 
contrast, CYP2D6 activity towards DM would be overestimated for 
7) and only two non-Caucasian subjects with a tandem hybrid 
(case 13, an Indo-Trinidadian and an African American described 
previously (Gaedigk et al., 2010), both having a CYP2D6*76 + *1). 
In contrast, all three subjects with a CYP2D7[REP6] are of African 
ancestry (cases 10, 11, and 12).
We estimate the combined frequency of “single” hybrid genes at 
0.1–1% in Caucasians and <0.1% in African Americans. This estimate 
is based on three cohorts which have systematically been interro-
gated for single as well as tandem hybrids. We have also screened an 
African American cohort for both single and tandem hybrids and 
only found a single individual with a hybrid, i.e., CYP2D6*76 + *1 
(Gaedigk et al., 2010) further supporting a low frequency of such 
alleles in subjects of African ancestry. Before we started to routinely 
screen for such alleles we selected only samples presenting with rare 
homozygous genotypes such as CYP2D6*5/*5 (index case) or *6/*6 
(case 6) for hybrid testing. The latter case, a Caucasian who was 
revised to CYP2D6*6/*67, was part of an ethnically mixed cohort of 
285 subjects collected in Albany, NY. However, it remains unknown 
whether any other homozygous individuals of that sample cohort 
carry hybrids. Other cases were selected for a more complete char-
acterization for a number of reasons. Case 3 for instance was tested 
with the AmpliChip P450 test in a diagnostic setting and revealed 
inconsistencies with the genotype of confirmed family members. 
Identification of a CYP2D6*66 resolved these inconsistencies. Case 
9 on the other hand initially revealed a genotype that was discordant 
with phenotype. This example illustrates how an unknown sequence 
variation can interfere with the genotyping procedure, i.e., prohibit 
primer binding, and thereby cause an incorrect genotype assignment. 
Unfortunately, a systematic re-evaluation of entire corresponding 
cohorts from which these cases were extracted was not feasible due 
to DNA availability, quality and/or expired patient consent.
We did not observe any single or tandem hybrids other than 
CYP2D6*36 + *10 in the 50 Asian subjects among our collection. 
The CYP2D6*36 gene harboring the CYP2D7 exon 9 conversion 
on  an  otherwise  CYP2D6  background  in  combination  with  a 
CYP2D6*10 (also referred to as CYP2D6*36 + *10) is frequently 
detected when discriminated from the “single” CYP2D6*10 allele 
(Ramamoorthy et al., 2010). While we are not aware of any other 
evidence that would suggest the presence of CYP2D7/2D6 hybrids in 
Asians, larger population samples would need to be investigated.
In  single  and  tandem  configuration,  hybrid  genes  with  a 
CYP2D7/2D6 switch beyond exon 1 are non-functional due to a 
T-insertion in this exon that leads to premature termination. A 
relatively simple strategy for hybrid detection and genotyping is to 
amplify a 5-kb-long PCR product and test for the presence of the 
T-insertion. We now routinely co-amplify this 5-kb-long ampli-
con (i.e., fragment H) along a duplication-specific fragment and 
a 6.6-kb-long product encompassing CYP2D6 as described previ-
ously (Gaedigk et al., 2010). This triplex PCR not only provides 
information regarding the presence or absence of a hybrid and/or 
duplication, but can also be used as template to genotype for the 
T-insertion. An alternative strategy to detect hybrid genes in single 
and tandem configuration is to determine gene copy number in a 
quantitative manner. However, as discussed by Ramamoorthy et al. 
(2010), the selection of assay, i.e. which part of the gene is interro-
gated, is crucial. We have established quantitative assays that probe 
in four different regions of the CYP2D6 gene (exon 1, intron 5, www.frontiersin.org  October 2010  | Volume 1  | Article 121  |  9
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heterogeneity of the CYP2D gene locus. Furthermore, consistent 
discovery of additional cases with known and novel hybrids in 
different configurations and subjects of different ethnic and geo-
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than initially believed. Their detection may improve the accuracy of 
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cases 1, 3, 7, and 8 because these subjects carry only one and not 
two copies of a functional or reduced activity allele. For example, 
case 1 would be misclassified as CYP2D6*9/*9 with an activity 
score (AS) of 1.5 predicting an EM phenotype while the accurate 
CYP2D6*9/*66 genotype with an AS of 0.5 predicted this individual 
to present as an intermediate metabolizer (Gaedigk et al., 2008).
CYP2D7 genes lacking the 1.6-kb spacer sequence (referred 
to as CYP2D7[REP6]) and positioned upstream of a functional 
CYP2D6 complicated the characterization and interpretation of 
true CYP2D7/2D6 hybrid genes by also forming the 5-kb-long 
fragment H. It was distinguished from the other hybrid genes 
by being CYP2D7 throughout exon 9 and being negative for any 
amplification with primers specific for CYP2D7 and a sequence 
on the far 3′-end of the CYP2D locus as outlined in Figures 
1B,C. In contrast, single hybrid genes support such amplicons. 
Furthermore, quantitative copy number determination including 
CYP2D6 and CYP2D7 supported the CYP2D7[REP6] structure 
shown in Figure 3.
In summary, our recent discoveries of recombination events 
creating hybrid genes in single and tandem rearrangements sug-
gest that such events contribute significantly to the high degree of 